Smith Chas P Associates Pa Cpas Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Smith Chas P Associates Pa Cpas reduced its stake in Abbott Laboratories by 9.35% during the most recent quarter end. The investment management company now holds a total of 68,326 shares of Abbott Laboratories which is valued at $3,071,254 after selling 7,049 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Abbott Laboratories makes up approximately 0.51% of Smith Chas P Associates Pa Cpas’s portfolio.

Other Hedge Funds, Including , Buckingham Asset Management reduced its stake in ABT by selling 8,492 shares or 30.47% in the most recent quarter. The Hedge Fund company now holds 19,380 shares of ABT which is valued at $871,131. Abbott Laboratories makes up approx 0.29% of Buckingham Asset Management’s portfolio.Community Bank Trust Waco Texas reduced its stake in ABT by selling 850 shares or 2.24% in the most recent quarter. The Hedge Fund company now holds 37,131 shares of ABT which is valued at $1,621,511. Abbott Laboratories makes up approx 0.87% of Community Bank Trust Waco Texas’s portfolio.Btr Capital Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 12,090 additional shares and now holds a total of 126,625 shares of Abbott Laboratories which is valued at $5,329,646. Abbott Laboratories makes up approx 1.18% of Btr Capital Management Inc’s portfolio.Dalton Greiner Hartman Maher Co reduced its stake in ABT by selling 57,090 shares or 16.24% in the most recent quarter. The Hedge Fund company now holds 294,383 shares of ABT which is valued at $12,355,255. Abbott Laboratories makes up approx 0.74% of Dalton Greiner Hartman Maher Co’s portfolio.Cohen Lawrence B boosted its stake in ABT in the latest quarter, The investment management firm added 6,775 additional shares and now holds a total of 98,484 shares of Abbott Laboratories which is valued at $4,125,495. Abbott Laboratories makes up approx 2.42% of Cohen Lawrence B’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.